Patients with osteoporosis have an increased risk of fractures owing to a loss in bone strength, which can place a considerable burden on healthcare systems. A significant unmet need exists for treatment that is safer, more-efficacious, and that will improve patient compliance. We discuss how current therapies are differentiated based on performance of key drug attributes, and measure the impact of these attributes on rheumatologists’ and endocrinologists’ prescribing behavior. We also discuss the most important unmet needs in the treatment of osteoporosis and consider which emerging therapies, if any, can capitalize on these opportunities. Our conjoint analysis reveals the trade-offs in key attributes, such as risk of fracture, safety, dosing burden, and price, that surveyed physicians are willing to make when considering new treatment options for osteoporosis.
- What are the treatment drivers and goals for osteoporosis?
- What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for osteoporosis?
- What are the prevailing areas of unmet need and opportunity in osteoporosis?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European rheumatologists and endocrinologists for a hypothetical new osteoporosis drug?
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, and Germany.
Primary research: Survey of 60 U.S. and 30 European rheumatologists and endocrinologists fielded in January 2018.
Key companies: Amgen, Eli Lilly, Merck, Novartis, Pfizer, Radius Health, and UCB.
Key drugs: Evenity, Forteo, Prolia, and Tymlos.